The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
Huntingtin Lowering Strategies for Disease Modification in Huntington’s Disease
Open accessAbstract
Huntington's disease is caused by an abnormally expanded CAG repeat expansion in the HTT gene, which confers a predominant toxic gain of function in the mutant huntingtin (mHTT) protein. There are currently no disease-modifying therapies available, but approaches that target proximally in disease pathogenesis hold great promise. These include DNA-targeting techniques such as zinc-finger proteins, transcription activator-like effector nucleases, and CRISPR/Cas9; post-transcriptional huntingtin-lowering approaches such as RNAi, antisense oligonucleotides, and small-molecule splicing modulators; and novel methods to clear the mHTT protein, such as proteolysis-targeting chimeras. Improvements in the delivery and distribution of such agents as well as the development of objective biomarkers of disease and of HTT lowering pharmacodynamic outcomes have brought these potential therapies to the forefront of Huntington's disease research, with clinical trials in patients already underway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Regulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,743
Self-citationFatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
Self-citationIntravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Mercuri, E., Darras, B. T., Chiriboga, C. A., Day, J. W., Campbell, C., Connolly, A. M., Iannaccone, S. T., Kirschner, J., Kuntz, N. L., Saito, K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710504 · Cited by 1,433
Activation of the interferon system by short-interfering RNAs
Sledz, C. A., Holko, M., de Veer, M. J., Silverman, R. H., & Williams, B. R. G. (2003) · Nature Cell Biology · doi:10.1038/ncb1038 · Cited by 1,400
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Therapeutic genome editing: prospects and challenges
Cox, D. B. T., Platt, R. J., & Zhang, F. (2015) · Nature Medicine · doi:10.1038/nm.3793 · Cited by 1,336
Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,232
Lipid Nanoparticle Systems for Enabling Gene Therapies
Cullis, P. R., & Hope, M. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.013 · Cited by 1,208
Jackson, A. L., & Linsley, P. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3010 · Cited by 1,083
Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease
Yamamoto, A., Lucas, J. J., & Hen, R. (2000) · Cell · doi:10.1016/s0092-8674(00)80623-6 · Cited by 1,067
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Deverman, B. E., Pravdo, P. L., Simpson, B. P., Kumar, S. R., Chan, K. Y., Banerjee, A., Wu, W.-L., Yang, B., Huber, N., Pasca, S. P., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3440 · Cited by 1,061
Finkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J. W., Montes, J., De Vivo, D. C., Yamashita, M., Rigo, F., Hung, G., Schneider, E., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31408-8 · Cited by 1,019
Huntington disease: natural history, biomarkers and prospects for therapeutics
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016
Self-citationSaudou, F., & Humbert, S. (2016) · Neuron · doi:10.1016/j.neuron.2016.02.003 · Cited by 951
Nasir, J., Floresco, S. B., O'Kusky, J. R., Diewert, V. M., Richman, J. M., Zeisler, J., Borowski, A., Marth, J. D., Phillips, A. G., & Hayden, M. R. (1995) · Cell · doi:10.1016/0092-8674(95)90542-1 · Cited by 872
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Tabrizi, S. J., Scahill, R. I., Owen, G., Durr, A., Leavitt, B. R., Roos, R. A., Borowsky, B., Landwehrmeyer, B., Frost, C., Johnson, H., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70088-7 · Cited by 846
Self-citationZeitlin, S., Liu, J.-P., Chapman, D. L., Papaioannou, V. E., & Efstratiadis, A. (1995) · Nature Genetics · doi:10.1038/ng1095-155 · Cited by 802
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease
Slow, E. J. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg169 · Cited by 800
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
The Discovery of Zinc Fingers and Their Applications in Gene Regulation and Genome Manipulation
Klug, A. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-010909-095056 · Cited by 710
Harper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682
Identification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease
Lee, J.-M., Wheeler, V. C., Chao, M. J., Vonsattel, J. P. G., Pinto, R. M., Lucente, D., Abu-Elneel, K., Ramos, E. M., Mysore, J. S., Gillis, T., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.003 · Cited by 655
Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
McBride, J. L., Boudreau, R. L., Harper, S. Q., Staber, P. D., Monteys, A. M., Martins, I., Gilmore, B. L., Burstein, H., Peluso, R. W., Polisky, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801775105 · Cited by 607
Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood
Zetterberg, H., Smith, D. H., & Blennow, K. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.9 · Cited by 596
Dragatsis, I., Levine, M. S., & Zeitlin, S. (2000) · Nature Genetics · doi:10.1038/81593 · Cited by 576
Role of brain-derived neurotrophic factor in Huntington's disease
ZUCCATO, C., & CATTANEO, E. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.01.003 · Cited by 552
Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease
Sathasivam, K., Neueder, A., Gipson, T. A., Landles, C., Benjamin, A. C., Bondulich, M. K., Smith, D. L., Faull, R. L. M., Roos, R. A. C., Howland, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221891110 · Cited by 528
SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
Naryshkin, N. A., Weetall, M., Dakka, A., Narasimhan, J., Zhao, X., Feng, Z., Ling, K. K. Y., Karp, G. M., Qi, H., Woll, M. G., et al. (2014) · Science · doi:10.1126/science.1250127 · Cited by 524
Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro
Trushina, E., Dyer, R. B., Badger, J. D., Ure, D., Eide, L., Tran, D. D., Vrieze, B. T., Legendre-Guillemin, V., McPherson, P. S., Mandavilli, B. S., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.18.8195-8209.2004 · Cited by 520
DeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Kebodeaux, C. S., Wegener, A. J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0481 · Cited by 516
Karikó, K., Bhuyan, P., Capodici, J., & Weissman, D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.6545 · Cited by 449
Sioud, M. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.03.013 · Cited by 418
Lunkes, A., Lindenberg, K. S., Ben-Haı̈em, L., Weber, C., Devys, D., Landwehrmeyer, G. B., Mandel, J.-L., & Trottier, Y. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00602-0 · Cited by 416
DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pandey, R. K., Rajeev, K. G., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708285104 · Cited by 415
CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease
Yang, S., Chang, R., Yang, H., Zhao, T., Hong, Y., Kong, H. E., Sun, X., Qin, Z., Jin, P., Li, S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92087 · Cited by 399
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion
Lee, J.-M., Ramos, E. M., Lee, J.-H., Gillis, T., Mysore, J. S., Hayden, M. R., Warby, S. C., Morrison, P., Nance, M., Ross, C. A., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318249f683 · Cited by 382
Self-citationKennedy, L. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg352 · Cited by 380
Byrne, L. M., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A. C., Scahill, R. I., Tabrizi, S. J., Zetterberg, H., Langbehn, D., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30124-2 · Cited by 364
Self-citationArtificial MicroRNAs as siRNA Shuttles: Improved Safety as Compared to shRNAs In vitro and In vivo
Boudreau, R. L., Martins, I., & Davidson, B. L. (2009) · Molecular Therapy · doi:10.1038/mt.2008.231 · Cited by 359
Pre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Louis Jeune, V., Joergensen, J. A., Hajjar, R. J., & Weber, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.243 · Cited by 358
Choosing an animal model for the study of Huntington's disease
Pouladi, M. A., Morton, A. J., & Hayden, M. R. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3570 · Cited by 356
Mutant Huntingtin Disrupts the Nuclear Pore Complex
Grima, J. C., Daigle, J. G., Arbez, N., Cunningham, K. C., Zhang, K., Ochaba, J., Geater, C., Morozko, E., Stocksdale, J., Glatzer, J. C., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.03.023 · Cited by 356
RAN Translation in Huntington Disease
Bañez-Coronel, M., Ayhan, F., Tarabochia, A. D., Zu, T., Perez, B. A., Tusi, S. K., Pletnikova, O., Borchelt, D. R., Ross, C. A., Margolis, R. L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.10.038 · Cited by 354
Boudreau, R. L., McBride, J. L., Martins, I., Shen, S., Xing, Y., Carter, B. J., & Davidson, B. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.17 · Cited by 339
Swami, M., Hendricks, A. E., Gillis, T., Massood, T., Mysore, J., Myers, R. H., & Wheeler, V. C. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp242 · Cited by 327
Landles, C., Sathasivam, K., Weiss, A., Woodman, B., Moffitt, H., Finkbeiner, S., Sun, B., Gafni, J., Ellerby, L. M., Trottier, Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.075028 · Cited by 326
Moss, D. J. H., Pardiñas, A. F., Langbehn, D., Lo, K., Leavitt, B. R., Roos, R., Durr, A., Mead, S., Coleman, A., Santos, R. D., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30161-8 · Cited by 312
Self-citationCRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo
Monteys, A. M., Ebanks, S. A., Keiser, M. S., & Davidson, B. L. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.010 · Cited by 309
Therapies targeting DNA and RNA in Huntington's disease
Wild, E. J., & Tabrizi, S. J. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30280-6 · Cited by 298
Self-citationAmbrose, C. M., Duyao, M. P., Barnes, G., Bates, G. P., Lin, C. S., Srinidhi, J., Baxendale, S., Hummerich, H., Lehrach, H., Altherr, M., et al. (1994) · Somatic Cell and Molecular Genetics · doi:10.1007/bf02257483 · Cited by 278
Overexpression of Exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs
YI, R., DOEHLE, B. P., QIN, Y., MACARA, I. G., & CULLEN, B. R. (2005) · RNA · doi:10.1261/rna.7233305 · Cited by 278
Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9
Shin, J. W., Kim, K.-H., Chao, M. J., Atwal, R. S., Gillis, T., MacDonald, M. E., Gusella, J. F., & Lee, J.-M. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw286 · Cited by 276
Rodriguez-Lebron, E., Denovan-Wright, E. M., Nash, K., Lewin, A. S., & Mandel, R. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.05.006 · Cited by 275
Wild, E. J., Boggio, R., Langbehn, D., Robertson, N., Haider, S., Miller, J. R. C., Zetterberg, H., Leavitt, B. R., Kuhn, R., Tabrizi, S. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80743 · Cited by 268
Self-citationPfister, E. L., Kennington, L., Straubhaar, J., Wagh, S., Liu, W., DiFiglia, M., Landwehrmeyer, B., Vonsattel, J.-P., Zamore, P. D., & Aronin, N. (2009) · Current Biology · doi:10.1016/j.cub.2009.03.030 · Cited by 261
Advances in therapeutic CRISPR/Cas9 genome editing
Savić, N., & Schwank, G. (2016) · Translational Research · doi:10.1016/j.trsl.2015.09.008 · Cited by 257
McBride, J. L., Pitzer, M. R., Boudreau, R. L., Dufour, B., Hobbs, T., Ojeda, S. R., & Davidson, B. L. (2011) · Molecular Therapy · doi:10.1038/mt.2011.219 · Cited by 247
Neueder, A., Landles, C., Ghosh, R., Howland, D., Myers, R. H., Faull, R. L. M., Tabrizi, S. J., & Bates, G. P. (2017) · Scientific Reports · doi:10.1038/s41598-017-01510-z · Cited by 233
Self-citationDelivery Vehicles for Small Interfering RNA In Vivo
de Fougerolles, A. R. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.928 · Cited by 226
Rafii, M. S., Tuszynski, M. H., Thomas, R. G., Barba, D., Brewer, J. B., Rissman, R. A., Siffert, J., Aisen, P. S., & for the AAV2-NGF Study Team (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0233 · Cited by 219
Xu, X., Tay, Y., Sim, B., Yoon, S.-I., Huang, Y., Ooi, J., Utami, K. H., Ziaei, A., Ng, B., Radulescu, C., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.01.022 · Cited by 219
Sustained effects of nonallele‐specific Huntingtin silencing
Drouet, V., Perrin, V., Hassig, R., Dufour, N., Auregan, G., Alves, S., Bonvento, G., Brouillet, E., Luthi‐Carter, R., Hantraye, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21569 · Cited by 216
Wang, N., Gray, M., Lu, X.-H., Cantle, J. P., Holley, S. M., Greiner, E., Gu, X., Shirasaki, D., Cepeda, C., Li, Y., et al. (2014) · Nature Medicine · doi:10.1038/nm.3514 · Cited by 205
Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice
Garriga-Canut, M., Agustín-Pavón, C., Herrmann, F., Sánchez, A., Dierssen, M., Fillat, C., & Isalan, M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206506109 · Cited by 194
Byrne, L. M., Rodrigues, F. B., Johnson, E. B., Wijeratne, P. A., De Vita, E., Alexander, D. C., Palermo, G., Czech, C., Schobel, S., Scahill, R. I., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7108 · Cited by 194
Hammond, S. M., Hazell, G., Shabanpoor, F., Saleh, A. F., Bowerman, M., Sleigh, J. N., Meijboom, K. E., Zhou, H., Muntoni, F., Talbot, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1605731113 · Cited by 193
Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA
Wang, Y.-L., Liu, W., Wada, E., Murata, M., Wada, K., & Kanazawa, I. (2005) · Neuroscience Research · doi:10.1016/j.neures.2005.06.021 · Cited by 191
Biology of adeno-associated viral vectors in the central nervous system
Murlidharan, G., Samulski, R. J., & Asokan, A. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00076 · Cited by 191
The cryo-electron microscopy structure of huntingtin
Guo, Q., Huang, B., Cheng, J., Seefelder, M., Engler, T., Pfeifer, G., Oeckl, P., Otto, M., Moser, F., Maurer, M., et al. (2018) · Nature · doi:10.1038/nature25502 · Cited by 187
Van Raamsdonk, J. M., Pearson, J., Rogers, D. A., Bissada, N., Vogl, A. W., Hayden, M. R., & Leavitt, B. R. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi147 · Cited by 173
Self-citationMatsuzaki, Y., Konno, A., Mochizuki, R., Shinohara, Y., Nitta, K., Okada, Y., & Hirai, H. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2017.11.049 · Cited by 173
Evers, M. M., Miniarikova, J., Juhas, S., Vallès, A., Bohuslavova, B., Juhasova, J., Skalnikova, H. K., Vodicka, P., Valekova, I., Brouwers, C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.06.021 · Cited by 168
FAN1 modifies Huntington’s disease progression by stabilizing the expanded HTT CAG repeat
Goold, R., Flower, M. D., Moss, D. J. H., Medway, C., Wood‐Kaczmar, A., André, R., Farshim, P. P., Bates, G. P., Holmans, P., Jones, L., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy375 · Cited by 166
Self-citationStanek, L. M., Sardi, S. P., Mastis, B., Richards, A. R., Treleaven, C. M., Taksir, T., Misra, K., Cheng, S. H., & Shihabuddin, L. S. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.200 · Cited by 162
Franich, N. R., Fitzsimons, H. L., Fong, D. M., Klugmann, M., During, M. J., & Young, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.50 · Cited by 161
Development of biomarkers for Huntington's disease
Weir, D. W., Sturrock, A., & Leavitt, B. R. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70070-9 · Cited by 161
Self-citationSouthwell, A. L., Skotte, N. H., Kordasiewicz, H. B., Østergaard, M. E., Watt, A. T., Carroll, J. B., Doty, C. N., Villanueva, E. B., Petoukhov, E., Vaid, K., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.153 · Cited by 158
Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum
Grondin, R., Kaytor, M. D., Ai, Y., Nelson, P. T., Thakker, D. R., Heisel, J., Weatherspoon, M. R., Blum, J. L., Burright, E. N., Zhang, Z., et al. (2012) · Brain · doi:10.1093/brain/awr333 · Cited by 153
Wang, G., Liu, X., Gaertig, M. A., Li, S., & Li, X.-J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524575113 · Cited by 146
Ratovitski, T., Guček, M., Jiang, H., Chighladze, E., Waldron, E., D'Ambola, J., Hou, Z., Liang, Y., Poirier, M. A., Hirschhorn, R. R., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m804813200 · Cited by 144
Discovery of Small Molecules that Induce the Degradation of Huntingtin
Tomoshige, S., Nomura, S., Ohgane, K., Hashimoto, Y., & Ishikawa, M. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201706529 · Cited by 144
Skotte, N. H., Southwell, A. L., Østergaard, M. E., Carroll, J. B., Warby, S. C., Doty, C. N., Petoukhov, E., Vaid, K., Kordasiewicz, H. B., Watt, A. T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107434 · Cited by 139
REGISTRY Investigators of the European Huntington's Disease Network, Bečanović, K., Nørremølle, A., Neal, S. J., Kay, C., Collins, J. A., Arenillas, D., Lilja, T., Gaudenzi, G., Manoharan, S., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4014 · Cited by 135
Self-citationMiniarikova, J., Zanella, I., Huseinovic, A., van der Zon, T., Hanemaaijer, E. S., Martier, R., Koornneef, A., Southwell, A. L., Hayden, M. R., van Deventer, S. J. H., et al. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.7 · Cited by 131
The Self-Inactivating KamiCas9 System for the Editing of CNS Disease Genes
Mérienne, N., Vachey, G., de Longprez, L., Meunier, C., Zimmer, V., Perriard, G., Canales, M., Mathias, A., Herrgott, L., Beltraminelli, T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.075 · Cited by 130
rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse
Machida, Y., Okada, T., Kurosawa, M., Oyama, F., Ozawa, K., & Nukina, N. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.02.141 · Cited by 128
Huntingtin suppression restores cognitive function in a mouse model of Huntington’s disease
Southwell, A. L., Kordasiewicz, H. B., Langbehn, D., Skotte, N. H., Parsons, M. P., Villanueva, E. B., Caron, N. S., Østergaard, M. E., Anderson, L. M., Xie, Y., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3959 · Cited by 126
Keiser, M. S., Kordasiewicz, H. B., & McBride, J. L. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv442 · Cited by 123
Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases
Dabrowska, M., Juzwa, W., Krzyżosiak, W. J., & Olejniczak, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00075 · Cited by 121
Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities
Harding, R., & Tong, Y. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2018.11 · Cited by 120
Southwell, A. L., Smith, S. E. P., Davis, T. R., Caron, N. S., Villanueva, E. B., Xie, Y., Collins, J. A., Ye, M. L., Sturrock, A., Leavitt, B. R., et al. (2015) · Scientific Reports · doi:10.1038/srep12166 · Cited by 111
Self-citationMartin, J. N., Wolken, N., Brown, T., Dauer, W. T., Ehrlich, M. E., & Gonzalez‐Alegre, P. (2011) · Gene Therapy · doi:10.1038/gt.2011.10 · Cited by 109
Reidling, J. C., Relaño-Ginés, A., Holley, S. M., Ochaba, J., Moore, C., Fury, B., Lau, A., Tran, A. H., Yeung, S. Y., Salamati, D., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.11.005 · Cited by 101
Graham, R. K., Slow, E., Deng, Y., Bissada, N., Lu, G., Pearson, J., Shehadeh, J., Leavitt, B. R., Raymond, L. A., & Hayden, M. R. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.007 · Cited by 99
Self-citationSpt4 Is Selectively Required for Transcription of Extended Trinucleotide Repeats
Liu, C.-R., Chang, C., Chern, Y., Wang, T.-H., Hsieh, W.-C., Shen, W.-C., Chang, C.-Y., Chu, I.-C., Deng, N., Cohen, S. N., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.032 · Cited by 97
Neurofilament light protein in blood predicts regional atrophy in Huntington disease
Johnson, E. B., Byrne, L. M., Gregory, S., Rodrigues, F. B., Blennow, K., Dürr, A., Leavitt, B. R., Roos, R. A. C., Zetterberg, H., Tabrizi, S. J., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005005 · Cited by 96
Self-citationMittelman, D., Moye, C., Morton, J. J., Sykoudis, K., Lin, Y., Carroll, D., & Wilson, J. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902420106 · Cited by 94
Brain-specific Proteins Decline in the Cerebrospinal Fluid of Humans with Huntington Disease
Fang, Q., Strand, A. D., Law, W., Faça, V. M., Fitzgibbon, M., Hamel, N., Houle, B., Liu, X., May, D., Poschmann, G., et al. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800231-mcp200 · Cited by 92
Self-citationKolli, N., Lü, M., Maiti, P., Rossignol, J., & Dunbar, G. L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040754 · Cited by 91
Ex vivo gene therapy for the treatment of neurological disorders
Gowing, G., Svendsen, S. P., & Svendsen, C. N. (2017) · Progress in brain research · doi:10.1016/bs.pbr.2016.11.003 · Cited by 88
Travessa, A., Rodrigues, F. B., Mestre, T., & Ferreira, J. J. (2017) · Journal of Huntington s Disease · doi:10.3233/jhd-170245 · Cited by 85
Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease
Rodrigues, F. B., Byrne, L. M., McColgan, P., Robertson, N., Tabrizi, S. J., Leavitt, B. R., Zetterberg, H., & Wild, E. J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13719 · Cited by 84
Self-citationHeman-Ackah, S. M., Bassett, A. R., & Wood, M. J. A. (2016) · Scientific Reports · doi:10.1038/srep28420 · Cited by 83
Fink, K. D., Deng, P., Gutierrez, J., Anderson, J. S., Torrest, A., Komarla, A., Kalomoiris, S., Cary, W., Anderson, J. D., Gruenloh, W., et al. (2016) · Cell Transplantation · doi:10.3727/096368916x690863 · Cited by 81
Dufour, B. D., Smith, C. A., Clark, R. L., Walker, T. R., & McBride, J. L. (2014) · Molecular Therapy · doi:10.1038/mt.2013.289 · Cited by 77
Datson, N. A., González‐Barriga, A., Kourkouta, E., Weij, R., van de Giessen, J., Mulders, S. A. M., Kontkanen, O., Heikkinen, T., Lehtimäki, K. K., & van Deutekom, J. C. T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171127 · Cited by 76
Clinical Applications Involving CNS Gene Transfer
Kantor, B., McCown, T., Leone, P., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00002-0 · Cited by 74
Highly Specific Contractions of a Single CAG/CTG Trinucleotide Repeat by TALEN in Yeast
Richard, G., Viterbo, D., Khanna, V., Mosbach, V., Castelain, L., & Dujon, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095611 · Cited by 70
Agustín‐Pavón, C., Mielcarek, M., Garriga-Canut, M., & Isalan, M. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0128-x · Cited by 70
Targeting CAG repeat RNAs reduces Huntington’s disease phenotype independently of huntingtin levels
Rué, L., Báñez-Coronel, M., Creus‐Muncunill, J., Giralt, A., Alcalá‐Vida, R., Mentxaka, G., Kagerbauer, B., Zomeño-Abellán, M. T., Aranda, Z., Venturi, V., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83185 · Cited by 69
Stanek, L. M., Yang, W., Angus, S., Sardi, P., Hayden, M. R., Hung, G., Bennett, C. F., Cheng, S. H., & Shihabuddin, L. S. (2013) · Journal of Huntington s Disease · doi:10.3233/jhd-130057 · Cited by 68
Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference
Chen, Z. J., Kren, B. T., Wong, P. Y.-P., Low, W. C., & Steer, C. J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.02.024 · Cited by 66
Estrada‐Sánchez, A. M., Burroughs, C. L., Cavaliere, S., Barton, S. J., Chen, S., Yang, X. W., & Rebec, G. V. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.2812-14.2015 · Cited by 63
Constantinescu, R., Romer, M., Oakes, D., Rosengren, L., & Kieburtz, K. D. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.05.012 · Cited by 61
Subcellular Clearance and Accumulation of Huntington Disease Protein: A Mini-Review
Zhao, T., Hong, Y., Li, X., & Li, S.-H. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00027 · Cited by 61
“Huntingtin Holiday”: Progress toward an Antisense Therapy for Huntington's Disease
Lu, X., & Yang, X. W. (2012) · Neuron · doi:10.1016/j.neuron.2012.06.001 · Cited by 60
Is Huntingtin Dispensable in the Adult Brain?
Liu, J.-P., & Zeitlin, S. O. (2017) · Journal of Huntington s Disease · doi:10.3233/jhd-170235 · Cited by 59
Tomoshige, S., Nomura, S., Ohgane, K., Hashimoto, Y., & Ishikawa, M. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.01.012 · Cited by 59
Fodale, V., Boggio, R., Daldin, M., Cariulo, C., Spiezia, M. C., Byrne, L. M., Leavitt, B. R., Wild, E. J., Macdonald, D., Weiss, A., et al. (2017) · Journal of Huntington s Disease · doi:10.3233/jhd-170269 · Cited by 58
Self-citationPathogenic Mechanisms in Huntington's Disease
Jones, L., & Hughes, A. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-381328-2.00015-8 · Cited by 57
Delivering a disease-modifying treatment for Huntington's disease
Godinho, B. M. D. C., Malhotra, M., O’Driscoll, C. M., & Cryan, J. F. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.011 · Cited by 54
Testing a longitudinal compensation model in premanifest Huntington’s disease
Gregory, S., Long, J. D., Klöppel, S., Razi, A., Scheller, E., Minkova, L., Johnson, E. B., Dürr, A., Roos, R. A. C., Leavitt, B. R., et al. (2018) · Brain · doi:10.1093/brain/awy122 · Cited by 50
Self-citationWolf, D. A., Hesterman, J. Y., Sullivan, J. M., Orcutt, K. D., Silva, M. D., Lobo, M. R., Wellman, T. J., Hoppin, J., & Verma, A. (2016) · JCI Insight · doi:10.1172/jci.insight.85311 · Cited by 49
Borel, F., van Logtenstein, R., Koornneef, A., Maczuga, P., Ritsema, T., Petry, H., van Deventer, S. J. H., Jansen, P. L. M., & Konstantinova, P. S. (2011) · PubMed · Cited by 47
Papoutsi, M., Weiskopf, N., Langbehn, D. R., Reilmann, R., Rees, G. E., & Tabrizi, S. J. (2017) · Human Brain Mapping · doi:10.1002/hbm.23921 · Cited by 47
Self-citationModern Genome Editing Technologies in Huntington’s Disease Research
Malankhanova, T. B., Malakhova, A. A., Medvedev, S. P., & Zakian, S. M. (2017) · Journal of Huntington s Disease · doi:10.3233/jhd-160222 · Cited by 38
A Chemical Recipe for Generation of Clinical-Grade Striatal Neurons from hESCs
Wu, M., Zhang, D., Bi, C., Mi, T., Zhu, W., Xia, L., Teng, Z., Hu, B., & Wu, Y. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.08.005 · Cited by 38
Barik, S. (2006) · Nature Biotechnology · doi:10.1038/nbt0706-796 · Cited by 34
MSH3 Promotes Dynamic Behavior of Trinucleotide Repeat Tracts In Vivo
Williams, G. M., & Surtees, J. A. (2015) · Genetics · doi:10.1534/genetics.115.177303 · Cited by 33
Degradation of Misfolded Proteins by Autophagy: Is it a Strategy for Huntington's Disease Treatment?
Lin, F., & Qin, Z. (2013) · Journal of Huntington s Disease · doi:10.3233/jhd-130052 · Cited by 28
Tabrizi, S., Leavitt, B., Kordasiewicz, H., Czech, C., Swayze, E., Norris, D. A., Baumann, T., Gerlach, I., Schobel, S., Smith, A., et al. (2018) · Neurology · doi:10.1212/wnl.90.15_supplement.ct.002 · Cited by 26
Self-citationThe Role of Gene Editing in Neurodegenerative Diseases
Fan, H.-C., Chi, C.-S., Lee, Y.-J., Tsai, J., Lin, S., & Harn, H.-J. (2018) · Cell Transplantation · doi:10.1177/0963689717753378 · Cited by 23
Hersch, S. M., Claassen, D. O., Edmondson, M. C., Wild, E. J., Guerciolini, R., & Panzara, M. A. (2017) · Neurology · doi:10.1212/wnl.88.16_supplement.p2.006 · Cited by 15
Leavitt, B. R., Tabrizi, S. J., Kordasiewicz, H. B., Landwehrmeyer, G. B., Henry, S. P., Zanardi, T. A., Swayze, E. E., Norris, D. A., Smith, A. V., Lane, R. M., et al. (2016) · Neurology · doi:10.1212/wnl.86.16_supplement.pl01.002 · Cited by 7
Self-citationPathogenic mechanisms in Huntington's disease
Hughes, A., & Jones, L. (2014) · ORCA Online Research @Cardiff (Cardiff University) · Cited by 2
Cited by
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 538
Self-citationTabrizi, S. J., Estevez-Fraga, C., van Roon-Mom, W. M. C., Flower, M. D., Scahill, R. I., Wild, E. J., Muñoz-Sanjuan, I., Sampaio, C., Rosser, A. E., & Leavitt, B. R. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00121-1 · Cited by 331
Self-citationAntiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Barron, J. C., Hurley, E. P., & Parsons, M. P. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.689332 · Cited by 85
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
Li, X., Liu, Q., Xie, X., Peng, C., Pang, Q., Liu, B., & Han, B. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01712 · Cited by 46
Metadata
- Authors
- Tabrizi, S. J., Ghosh, R., & Leavitt, B. R.
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 101
- Issue
- 5
- Pages
- 801-819
- ISSN
- 0896-6273 (ISSN-L)
- OpenAlex
- W2919539529
- Cited by
- 337
- References
- 147
- FWCI
- 18.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.